Date published: 2026-2-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

ARHGAP (Rho GTPase activating protein) Inhibitoren

ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.

Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.

Siehe auch...

ProduktCAS #Katalog #MengePreisReferenzenBewertung

Fasudil, Monohydrochloride Salt

105628-07-7sc-203418
sc-203418A
sc-203418B
sc-203418C
sc-203418D
sc-203418E
sc-203418F
10 mg
50 mg
250 mg
1 g
2 g
5 g
10 g
¥203.00
¥372.00
¥982.00
¥1895.00
¥2854.00
¥5596.00
¥10267.00
5
(1)

ROCK-Inhibitor, der die ARHGAP-Aktivität durch eine verringerte Rückkopplung des Weges stabilisieren kann.

H-1152 dihydrochloride

451462-58-1sc-203592
sc-203592A
1 mg
5 mg
¥1173.00
¥4107.00
7
(1)

Ein weiterer Rho-Kinase-Inhibitor, der möglicherweise die regulierende Wirkung von ARHGAP39 auf Rho-GTPasen beeinflussen könnte.

EHT 1864

754240-09-0sc-361175
sc-361175A
10 mg
50 mg
¥2403.00
¥10030.00
12
(2)

Rac1-Inhibitor, der die ARHGAP-vermittelte Signalübertragung durch Stabilisierung von inaktivem Rac1 reduzieren könnte.

PHA-848125

802539-81-7sc-364581
sc-364581A
5 mg
10 mg
¥3430.00
¥6262.00
(0)

Hemmt Trio, einen GEF, der möglicherweise die ARHGAP-vermittelte GTPase-Aktivität verändert.

Rhosin

1173671-63-0sc-507401
25 mg
¥6262.00
(0)

Hemmt selektiv die Bindung von RhoA an GEF und moduliert möglicherweise die regulatorischen Wirkungen von ARHGAP.

Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor Inhibitor

509093-47-4sc-204013
5 mg
¥1839.00
2
(0)

Cdc42-aktivitätsspezifischer Inhibitor, könnte die regulatorische Wirkung von ARHGAP anpassen.

ZCL278

587841-73-4sc-507369
10 mg
¥1297.00
(0)

Cdc42-Inhibitor, der die von ARHGAP regulierten nachgeschalteten Prozesse beeinflussen könnte.

PAC 1

315183-21-2sc-203174
sc-203174A
10 mg
50 mg
¥1489.00
¥6047.00
1
(1)

Hemmt Cytohesine und beeinflusst möglicherweise indirekt die ARHGAP-Aktivität.

RKI-1447

1342278-01-6sc-472590
1 mg
¥3723.00
(0)

Hemmt die Interaktion zwischen JMY und RhoA und beeinflusst damit indirekt die Aktivität von ARHGAP innerhalb des Rho-GTPase-Wegs.